AMPK activation: a therapeutic target for type 2 diabetes?

QR Code

AMPK activation: a therapeutic target for type 2 diabetes?

Kimberly A Coughlan, Rudy J Valentine, Neil B Ruderman, Asish K Saha Endocrinology and Diabetes, Department of Medicine, Boston University Medical Center, Boston, MA, USA Abstract: Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell dysfunction, and el...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Coughlan KA, Valentine RJ, Ruderman NB, Saha AK
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2014
Sujets:	Specialties of internal medicine RC581-951
Accès en ligne:	https://doaj.org/article/ef61d514b1eb41c3b14a4bfaab5498d9
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
par: Michael A Via, et autres
Publié: (2010)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
par: Seufert J
Publié: (2015)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review
par: Katrine B Hansen, et autres
Publié: (2010)

Saxagliptin for type 2 diabetes
par: Antonio R Chacra, et autres
Publié: (2010)

Sexual dysfunction in diabetic women: prevalence and differences in type 1 and type 2 diabetes mellitus
par: Mazzilli R, et autres
Publié: (2015)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
par: Kedia N
Publié: (2011)

Impact of physical activity and bodyweight on health-related quality of life in people with type 2 diabetes
par: Eckert K
Publié: (2012)

Type 2 diabetes in Brazil: epidemiology and management
par: Almeida-Pititto B, et autres
Publié: (2015)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
par: Whaley JM, et autres
Publié: (2012)

Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes
par: Mackenzie RWA, et autres
Publié: (2014)

Disturbance of inorganic phosphate metabolism in diabetes mellitus: temporary therapeutic intervention trials
par: J&oslash;rn Ditzel, et autres
Publié: (2009)

Linking obesity with type 2 diabetes: the role of T-bet
par: Wali JA, et autres
Publié: (2014)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
par: Rigato M, et autres
Publié: (2014)

Risk management in the treatment of type 2 diabetes with pioglitazone
par: Giuseppe Derosa, et autres
Publié: (2009)

Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor
par: Zheng X, et autres
Publié: (2015)

Expression of gluconeogenic enzymes and 11β-hydroxysteroid dehydrogenase type 1 in liver of diabetic mice after acute exercise
par: Brust KB, et autres
Publié: (2014)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
par: Gregory E Peterson
Publié: (2009)

Evidence for the benefit of exercise therapy in patients with type 2 diabetes
par: Madden KM
Publié: (2013)

Insulin detemir for the treatment of obese patients with type 2 diabetes
par: Hollander PA
Publié: (2012)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
par: Shannon A Miller, et autres
Publié: (2009)

Red cell distribution width in type 2 diabetic patients
par: Nada AM
Publié: (2015)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
par: Robert Moses
Publié: (2009)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
par: Pamela Kushner
Publié: (2010)

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
par: Henri K Parson, et autres
Publié: (2010)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
par: Joshua J Neumiller, et autres
Publié: (2010)

Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia
par: Anderson M, et autres
Publié: (2014)

Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
par: Sosale A, et autres
Publié: (2015)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
par: Kishimoto M
Publié: (2013)

Sex differences in type 2 diabetes: focus on disease course and outcomes
par: Arnetz L, et autres
Publié: (2014)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
par: Goud A, et autres
Publié: (2015)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
par: Gallwitz B
Publié: (2013)

Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation
par: Dara P Schuster
Publié: (2010)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
par: Bo Ahr&eacute;n
Publié: (2010)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
par: Holl, et autres
Publié: (2014)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
par: Jonathan K Reynolds
Publié: (2009)

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
par: Nishio S, et autres
Publié: (2015)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
par: Stanley S Schwartz
Publié: (2010)

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
par: Feher M, et autres
Publié: (2013)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
par: Omoto S, et autres
Publié: (2015)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
par: Paul Valensi
Publié: (2009)